Enhancement of latent inhibition in the rat by the CCK antagonist proglumide

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 4, 1998, Pages 1053-1059

  Gracey, David J ^a   Bell, Robert ^a   King, David J ^a   Trimble, Karen M ^a   McDermott, Barbara J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Haloperidol; Latent inhibition; Proglumide; Rat

Indexed keywords

CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; PROGLUMIDE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; DOPAMINE BRAIN LEVEL; DRUG USE; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SCHIZOPHRENIA;

ANIMALIA;

EID: 0032053139     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00533-9     Document Type: Article

References (57)

1. Baruch I., Hemsley D. R., Gray J. A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176:1988;598-606.
2. Bradwejn J., Koszycki D., Couetoux du Teretre A., Van Megen H. J. G. M., Westenberg H. G. M., Den Boer J. A., Karkanias C., Haigh J. The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist in patients with panic disorder. Arch. Gen. Psychiatry. 51:1994;486-493.
3. Chiodo L. A., Bunney B. S. Proglumide. Selective antagonism of excitatory effects of cholecystokinin in central nervous system Science. 219:1983;1449-1451.
4. Christison G. W., Atwater G. E., Dunn L. A., Kilts C. D. Haloperidol enhancement of latent inhibition. Relation to therapeutic action? Biol. Psychiatry. 23:1988;746-749.
5. Cohen S. L., Knight M., Tamminga C. A., Chase T. N. A. Cholecystokinin-octapeptide effects on conditoned-avoidance behavior, stereotypy and catalepsy. Eur. J. Pharmacol. 83:1982;213-222.
6. Crawley J. N., Fiske S. M., Evers J. R., Austin M. C., Beinfeld M. C. Multiple CCK receptors in the CNS. Dourish C. T., Cooper S. J., Iversen S. D., Iversen L. L. Functional analyses of the coexistence of CCK and dopamine. 1992;368-384 Oxford University Press, Oxford.
7. Crawley J. N., Corwin R. L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
8. Crawley J. N. Behavioural evidence for cholecystokinin modulation of dopamine in the mesolimbic pathways. Prog. Clin. Biol. Res. 192:1985;131-138.
9. Crawley J. N. CCK-dopamine interactions. Trends Pharmacol. Sci. 12:1991;232-236.
10. Csernansky J. G., Glick S., Mellentin J. Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function. Psychopharmacology (Berlin). 91:1987;440-444.
11. De La Casa L. G., Ruiz G., Lubow R. E. Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration. Implications for schizophrenia Biol. Psychiatry. 33:1993;707-711.
12. 3H] γ-aminobutyric acid release in slices from rat brain area. Eur. J. Pharmacol. 250:1993;423-430.
13. Dunn L. A., Atwater G. E., Kilts C. D. Effects of antipsychotic drugs on latent inhibition. Sensitivity and specficity of an animal model of clinical drug action Psychopharmacology (Berlin). 112:1993;315-323.
14. Ellenbroek B. A., Cools A. R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1:1990;469-490.
15. Feldon J., Weiner I. The Latent Inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rat's ability to ignore irrelevant stimuli. Biol. Psychiatry. 29:1991;635-646.
16. Gray A. S., Pickering A. D., Hemsley D. R., Dawling S., Gray J. A. Abolition of latent inhibition by a single 5mg dose of d-amphetamine in man. Psychopharmacology (Berlin). 107:1992;425-430.
17. Gray N. S., Hemsley D. R., Gray J. A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatr. Brain Res. 1:1992;83-89.
18. 3H-MK-329. J. Neurosci. 10:1990;1070-1081.
19. Hökfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature. 285:1980;476-477.
20. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective CCK type B receptor antagonists having potent anxiolytic activity. Proc. Natl. Acad. Sci. USA. 87:1990;6728-6732.
21. Killcross A. S., Dickinson A., Robbins T. W. Effects of the neuroleptic α-flupenthixol on LI in aversively and appetitively motivated paradigms. Evidence for dopamine-reinforcer interactions Psychopharmacology (Berlin). 115:1994;196-205.
22. Lubow R. E. Latent Inhibition and conditioned attention theory. 1989;Cambridge University Press, Cambridge, UK.
23. Marshall F. H., Barnes S., Pinnock R. D., Hughes J. Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro. Br. J. Pharmacol. 99:1990;845-848.
24. Meltzer H. Y., Stohl S. M. The dopamine hypothesis of schizophrenia. A review Schizophr. Bull. 2:1976;19-76.
25. Montgomery S. A., Green M. C. D. The use of cholecystokinin in schizophrenia. A review Psychol. Med. 18:1988;593-603.
26. Moran P. M., Fischer T. R., Hitchcock J. M., Moser P. C. Effects of clozapine on latent inhibition in the rat. Behav. Pharmacol. 7:1996;42-48.
27. 3 antagonist, facilitates latent inhibition in the rat. Pharmacol. Biochem. Behav. 42:1992;519-522.
28. Moran T. H., Robison P. H., Goldrich M. S., McHugh P. R. Two brain cholecystokinin receptors. Implications for behavioral actions Brain Res. 362:1986;175-179.
29. Peters S. L., Joseph M. H. Haloperidol potentiation of latent inhibition in rats. Evidence for a critical role at conditioning rather than preexposure Behav. Pharmacol. 4:1993;183-186.
30. Raiteri M., Paudice P., Vallebuona F. Release of cholecystokinin in the central nervous system. Neurochem. Int. 22:1993;519-527.
31. Rasmussen K., Czachura J. F., Stockton M. E., Howbert J. J. Electrophysiological effects of Diphenylpyrazolidinone CCK-B and CCK-A antagonists on midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 264:1993;480-488.
32. Rasmussen K., Stockton M. E., Czachura J. F., Howbert J. J. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691. Mediation through feedback pathways from forebrain sites. Pathways from forebrain sites Synapse. 15:1993;95-103.
33. B sites selectively. Dourish C. T., Cooper S. J., Iversen S. D., Iversen L. L. Functional analyses of the coexistence of CCK and dopamine. 1992;77-90 Oxford University Press, Oxford.
34. Rupniak N. M. J., Durieux C., Ruiz-Gayo M., Derrien M., Bergeron F., Corringer P. J., Dauge V. CCK-dopamine interactions. Implications for treatment of schizophrenia Multiple CCK receptors in the CNS. In: Dourish C. T., Cooper S. J., Iversen S. D., Iversen L. L. Functional analyses of the coexistence of CCK and dopamine. 1992;385-394 Oxford University Press, Oxford.
35. Schneider L. H., Alpert J. E., Iversen S. D. CCK-8 modulation of mesolimbic dopamine. Antagonism of amphetamine-stimulated behaviors Peptides. 4:1983;749-753.
36. Skirbol L. R., Grace A. A., Hommer D. W., Rehfeld J., Goldstein M., Hokfelt T., Bunney B. S. Peptide monamine coexistence. Studies of the action of a cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons Neuroscience. 6:1981;2111-2124.
37. Solomon P. R., Crider A., Winkelman J. W., Turi A., Kamer R. M., Kaplan L. J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity. Relationship to schizophrenic attention disorder Biol. Psychiatry. 16:1981;519-537.
38. Solomon P. R., Staton D. M. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore irrelevant stimulus. Biol. Psychiatry. 17:1982;743-756.
39. Treit D. Animal models for the study of anti-anxiety agents. A review Neurosci. Biobehav. Rev. 9:1985;203-222.
40. Trimble K. M., Bell R., King D. J. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol. Biochem. Behav. 56:1997;809-816.
41. Vaccarino F. J., Rankin J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity. Evidence for rostral-caudal differences in accumbens CCK function Behav. Neurosci. 103:1989;821-826.
42. Van Ree J. M., Gaffori O., De Wied D. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur. J. Pharmacol. 93:1983;63-78.
43. Van Ree J. M. Neuropetides and psychopathology. J. Controlled Release. 29:1994;307-315.
44. Warburton E. C., Joseph M. H., Feldon J., Weiner I., Gray J. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron; Implications for a possible antipsychotic action of ondansetron. Psychopharmacology (Berlin). 114:1994;657-664.
45. Weiner I., Lubow R. E., Feldon J. Chronic amphetamine and latent inhibition. Behav. Brain Res. 2:1981;285-286.
46. Weiner I., Lubow R. E., Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berlin). 83:1984;194-199.
47. Weiner I., Feldon J., Katz Y. Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol. Biochem. Behav. 26:1987;241-246.
48. Weiner I., Lubow R. E., Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmcol. Biochem. Behav. 30:1988;871-878.
49. Weiner I., Smith A. D., Rawlins J. N. P., Feldon J. A neuroleptic-like effect of ceronapril on latent inhibition. Neuroscience. 49:1992;307-315.
50. Weiner I., Tarrasch R., Hasson O., Forian R., Smith A. D., Rawlins J. N. P., Feldon J. The effects of chronic administration of ceronapril on the partial reinforcement extinction effect and latent inhibition in rats. Behav. Pharmacol. 5:1994;306-314.
51. Weiner I., Kidron R., Tarrasch R., Amt J., Feldon J. The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav. Pharmacol. 5:1994;119-124.
52. Weiner I., Shadach E., Tarrasch R., Kidron R., Feldon J. The latent inhibition animal model of schizophrenia. Further validation using the atypical neuroleptic, clozapine Biol. Psychiatry. 40:1996;834-843.
53. Weiner I., Feldon J. Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology (Berlin). 91:1987;248-253.
54. Weiner I. Neural substrates of latent inhibition. The switching model Psychol. Bull. 108:1990;442-461.
55. Whiteford H. A., Stedman T. J., Welham J. W., Csernansky J. G., Pond S. M. Placebo-controlled, double-blind study of the effects of proglumide in the reatment of schizophrenia. J. Clin. Psychopharmacol. 12:1992;337-340.
56. Williams J. H., Wellman N. A., Geaney D. P., Cowen P. J., Feldon J., Rawlins J. N. P. Antipsychotic drug effects in a model of schizophrenic attentional disorder. A randomized controlled trial of the effects of haloperidol on latent inhibition in healthy people Biol. Psychiatry. 40:1996;1135-1143.
57. Zetler G. Antisterotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced gnawing in sensitized rats. Neuropharmacology. 24:1985;251-259.